US 12,290,501 B2
Rivastigmine-containing transdermal absorption preparation
Satoshi Kawakami, Kagawa (JP); Manabu Sogabe, Kagawa (JP); and Taiki Shibata, Kagawa (JP)
Assigned to TEIKOKU SEIYAKU CO., LTD., Kagawa (JP)
Appl. No. 16/630,665
Filed by TEIKOKU SEIYAKU CO., LTD., Kagawa (JP)
PCT Filed Jul. 12, 2018, PCT No. PCT/JP2018/026279
§ 371(c)(1), (2) Date Jan. 13, 2020,
PCT Pub. No. WO2019/017266, PCT Pub. Date Jan. 24, 2019.
Claims priority of application No. 2017-139954 (JP), filed on Jul. 19, 2017.
Prior Publication US 2021/0085633 A1, Mar. 25, 2021
Int. Cl. A61K 31/27 (2006.01); A61K 9/06 (2006.01); A61K 47/34 (2017.01); A61K 47/38 (2006.01)
CPC A61K 31/27 (2013.01) [A61K 9/06 (2013.01); A61K 47/34 (2013.01); A61K 47/38 (2013.01)] 2 Claims
 
1. A transdermal absorption preparation comprising: an adhesive layer; the adhesive layer comprising:
5 mass % or more and 30 mass % or less of rivastigmine,
10 mass % or more and 60 mass % or less of a rubber polymer,
30 mass % or more and 70 mass % or less of a tackifier resin,
1 mass % or more and 20 mass % or less of a polymer compound having a nitrogen-containing group, and
0.1 mass % or more and 6 mass % or less of a cellulose derivative,
wherein the rubber polymer comprises a liquid polyisoprene rubber and a styrene-isoprene-styrene block copolymer,
wherein the cellulose derivative is hydroxypropyl methyl cellulose,
wherein the tackifier resin comprises a hydrogenated rosin glycerol ester, and an alicyclic saturated hydrocarbon resin, and
wherein the polymer compound having a nitrogen-containing group is a methyl methacrylate-butyl methacrylate-dimethylaminoethyl methacrylate copolymer.